Going Concern Warning, Ineffective Controls, and Deteriorating Financials Highlight Severe Risks

summarizeSummary

Cannabis Bioscience International Holdings, Inc. reported a going concern warning, ineffective disclosure controls, and deteriorating financial performance, including critically low cash and increasing losses.

check_boxKey Events

• Going Concern Warning Issued

  Management expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses, negative working capital of $(1,113,695), and negative cash flows from operations of $(109,205) for the six months ended November 30, 2025.

• Disclosure Controls Deemed Ineffective

  The principal executive and accounting officers concluded that the company's disclosure controls and procedures were not effective as of November 30, 2025.

• Critically Low Cash Position

  Cash and cash equivalents plummeted to $132 as of November 30, 2025, down from $12,952 at May 31, 2025, indicating severe liquidity issues.

• Deteriorating Financial Performance

  The company reported a net loss of $(116,966) for the quarter ended November 30, 2025, compared to $(79,528) in the prior year, alongside a significant decrease in revenues from clinical trial contracts.

auto_awesomeAnalysis

Cannabis Bioscience International Holdings, Inc. faces substantial doubt about its ability to continue as a going concern, as evidenced by recurring losses, negative working capital, and negative cash flows from operations. The company's cash position is critically low at $132, and its accumulated deficit has grown to over $6 million. Compounding these financial challenges, management has concluded that the company's disclosure controls and procedures were not effective, raising significant corporate governance concerns. The termination of its Pharmacology University business segment and extreme customer concentration (99% from three customers) further underscore the precarious operational and financial state, indicating a high risk for investors.